David A. Pattison

Butterfield St
Herston, QLD 4029, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 77 publications

177Lu-PSMA-617 SPECT/CT for Early Prediction of Overall Survival in Participants with Metastatic Castration-Resistant Prostate Cancer.

177Lu-PSMA-617 SPECT/CT for Early Prediction of Overall Survival in Participants with Metastatic Castration-Resistant Prostate Cancer.

Journal: Radiology

Published: April 28, 2026

Intrathyroid Parathyroid Adenoma Appearance on FCH PET/CT Imaging.

Intrathyroid Parathyroid Adenoma Appearance on FCH PET/CT Imaging.

Journal: ANZ journal of surgery

Published: April 14, 2026

A Buprenorphine Pocket Card and Tool Kit Tailored to Palliative Care Clinicians: An Education and Implementation Cohort Study.

A Buprenorphine Pocket Card and Tool Kit Tailored to Palliative Care Clinicians: An Education and Implementation Cohort Study.

Journal: Journal of palliative medicine

Published: March 20, 2026

[177Lu]Lu-DOTATATE PRRT and CAPTEM chemotherapy for pancreas and small bowel neuroendocrine tumours: The AGITG CONTROL NETS Multi-centre randomized trial.

[177Lu]Lu-DOTATATE PRRT and CAPTEM chemotherapy for pancreas and small bowel neuroendocrine tumours: The AGITG CONTROL NETS Multi-centre randomized trial.

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 26, 2026

Effect of [68Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trial.

Effect of [68Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trial.

Journal: The Lancet. Oncology

Published: February 13, 2026

Diagnosis of intermittent hydronephrosis on multiphase CT intravenous pyelogram and [99mTc]Tc-MAG3 study-Homsy sign.

Diagnosis of intermittent hydronephrosis on multiphase CT intravenous pyelogram and [99mTc]Tc-MAG3 study-Homsy sign.

Journal: Radiology case reports

Published: January 17, 2026

Prognostic Value of Interim PSMA-PET Total Tumor Volume for Overall Survival Within ENZA-p, A Randomized Phase 2 Trial of Enzalutamide Versus Enzalutamide Plus [177Lu] Lu-PSMA-617 (ANZUP1901).

Prognostic Value of Interim PSMA-PET Total Tumor Volume for Overall Survival Within ENZA-p, A Randomized Phase 2 Trial of Enzalutamide Versus Enzalutamide Plus [177Lu] Lu-PSMA-617 (ANZUP1901).

Journal: European urology

Published: December 14, 2025

Primary Hyperparathyroidism in Adults: Recent Developments in Diagnosis and Management.

Primary Hyperparathyroidism in Adults: Recent Developments in Diagnosis and Management.

Journal: The Medical journal of Australia

Published: September 30, 2025

Assessing Correlation of Quantitative Technetium-99m Sestamibi Uptake in Thyroid Scintigraphy With Treatment Duration in Amiodarone-Induced Thyrotoxicosis.

Assessing Correlation of Quantitative Technetium-99m Sestamibi Uptake in Thyroid Scintigraphy With Treatment Duration in Amiodarone-Induced Thyrotoxicosis.

Journal: Journal of medical imaging and radiation oncology

Published: September 30, 2025

Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial.

Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial.

Journal: The Lancet. Oncology

Published: April 26, 2025

Predictive value of early PSMA upregulation for the response to enzalutamide ± 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial.

Predictive value of early PSMA upregulation for the response to enzalutamide ± 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial.

Journal: Nature cancer

Published: March 25, 2025

A prospective, multi-centre trial of PSMA-PET compared to FDG-PET for staging of newly diagnosed high risk prostate cancer.

A prospective, multi-centre trial of PSMA-PET compared to FDG-PET for staging of newly diagnosed high risk prostate cancer.

Journal: EJNMMI research

Published: March 02, 2025

Showing 1-12 of 77

Last Updated: 09/26/2026